References

How I treat acute myeloid leukemia in the era of new drugs

10.1182/blood.2019001239 · 2020 · External reference

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

10.1056/nejmoa2012971 · 2020 · External reference

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis

10.3324/haematol.2019.242826 · 2020 · External reference

Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

10.1080/10428194.2022.2136952 · 2023 · External reference

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

10.1182/bloodadvances.2020003734 · 2021 · External reference

Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax

10.1002/cncr.33689 · 2021 · External reference

Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine

10.1158/1078-0432.ccr-22-1183 · 2022 · External reference

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

10.1038/s41375-024-02175-0 · 2024 · External reference

A phase 2 randomized study comparing venetoclax and azacitidine to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

10.1182/blood-2022-162525 · 2022 · External reference

Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60

10.1038/s41409-021-01476-7 · 2022 · External reference

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy

10.3324/haematol.2022.282677 · 2023 · External reference

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens

10.3324/haematol.2020.252569 · 2020 · External reference

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

10.1182/blood.2022016867 · 2022 · External reference

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

10.1182/blood-2017-03-772368 · 2017 · External reference

When less is more: reevaluating the role of intensive chemotherapy for older adults with acute myeloid leukemia in the modern era

10.1200/jco.21.00960 · 2021 · External reference

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

10.1182/blood-2010-03-276485 · 2010 · External reference

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia

10.1200/jco.2013.52.8562 · 2014 · External reference

Venetoclax in relapsed/refractory acute myeloid leukemia: are supporting evidences enough?

10.3390/cancers14010022 · 2021 · External reference